一种基于四面体DNA的人参皂苷Rg1递送纳米材料及其在制备抗心肌缺血药物中的应用
By delivering nanomaterials based on tetrahedral DNA-derived ginsenoside Rg1, the problems of low in vivo stability and bioavailability of Rg1 have been solved, enabling targeted drug delivery for myocardial ischemia-reperfusion injury. This significantly improves myocardial function and oxidative stress response, and has potential for clinical translation and industrialization.
CN121154841BActive Publication Date: 2026-07-17SHENZHEN BAOAN DISTRICT TRADITIONAL CHINESE MEDICINE HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN BAOAN DISTRICT TRADITIONAL CHINESE MEDICINE HOSPITAL
- Filing Date
- 2025-11-03
- Publication Date
- 2026-07-17
Smart Images
Figure CN121154841B_ABST
Abstract
本发明公开了一种基于四面体DNA的人参皂苷Rg1递送纳米材料及其在制备抗心肌缺血药物中的应用，纳米材料领域。本申请基于可编程寡核苷酸自组装技术，构建形成四面体DNA纳米结构（TDN），并通过引入含N₃修饰的CREKA心肌靶向肽段，实现精准连接与空间修饰，进一步负载人参皂苷Rg1，形成复合纳米药物系统Rg1@pTDN。材料全部为生物兼容成分，在体内具备良好的生物安全性和组织耐受性。Rg1@pTDN具备良好的心肌组织靶向能力与细胞摄取效率，可实现药物的稳定、靶向、高效递送，适用于MIRI、AMI等心血管疾病，具有临床转化与产业化潜力。
Need to check novelty before this filing date? Find Prior Art